Simulect and Lymphoma - a phase IV clinical study of FDA data

Summary:

Lymphoma is reported as a side effect among people who take Simulect (basiliximab), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Cellcept, and have Immunodeficiency disorders.

The phase IV clinical study analyzes which people have Lymphoma when taking Simulect. It is created by eHealthMe based on reports of 3,859 people who have side effects when taking Simulect from the FDA, and is updated regularly.

What is Simulect?

Simulect has active ingredients of basiliximab. eHealthMe is studying from 3,861 Simulect users. Check the latest studies of Simulect.

What is Lymphoma?

Lymphoma (cancer that begins in immune system cells) is found to be associated with 964 drugs and 1,013 conditions by eHealthMe. Check the latest studies of Lymphoma.

On Jun, 05, 2026

3,859 people reported to have side effects when taking Simulect.
Among them, 19 people (0.49%) have Lymphoma.

Among these 19 people:

* Approximation only. Some reports may have incomplete information.

Do you take Simulect and have Lymphoma?

- Check whether Lymphoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Simulect:

Simulect (3,861 reports)

Lymphoma treatments and more:

Lymphoma (33,395 reports)

How severe was Lymphoma and when was it recovered:

Lymphoma in Simulect

Expand to all the drugs that have ingredients of basiliximab:

Lymphoma and drugs with ingredients of basiliximab

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Simulect:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lymphoma:

Lymphoma (964 drugs)

Browse all the conditions that are associated with Lymphoma:

Lymphoma (1,013 conditions)

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .

How the study uses the data?

The study uses data from the FDA. It is based on basiliximab (the active ingredients of Simulect) and Simulect (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.